Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T18:51:10.586Z Has data issue: false hasContentIssue false
  • English
  • Français

Response of fetal tachycardia to transplacental procainamide therapy

Published online by Cambridge University Press:  19 August 2008

John K. Triedman ,
Edward P. Walsh  and
J. Philip Saul
John K. Triedman*
Affiliation:
Department of Cardiology, Children's Hospital, Boston
Edward P. Walsh
Affiliation:
Department of Cardiology, Children's Hospital, Boston
J. Philip Saul
Affiliation:
Department of Cardiology, Children's Hospital, Boston
*
Dr. John K.Triedman, Department of Cardiology, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115USA. Tel. 617-735-7893; Fax. 617-735-7513.
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe two fetuses presenting with hydrops and tachycardia who were treated by prolonged dosage with procainamide. Initial therapy with digoxin in both had been unsuccessful in controlling the rapid heart rate. The first child was delivered after five weeks of transplacental therapy, and demonstrated Wolff-Parkinson-White syndrome on the second day which was controlled with flecainide. The second fetus required three and a half weeks of intrauterine treatment. Wolff-Parkinson-White syndrome became manifest four days after premature labor at 33 weeks gestation. No tachycardia occurred postnatally and the infant has been well during follow-up. The implications of treatment are discussed.

Keywords

Fetal tachycardiaintrauterine therapydrug treatmentpharmacokinetics
Type
Brief Reports
Information
Cardiology in the Young , Volume 6 , Issue 3 , July 1996 , pp. 235 - 238
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cox, JL, Gardner, MJ.Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36: 137–178.Google Scholar
2.Zales, VR, Dunnigan, A, Benson, WB. JrClinical and electro-physiologic features of fetal and neonatal paroxysmal atrial tachycardia resulting in congestive heart failure. Am J Cardiol 1988; 62: 225–228.CrossRefGoogle Scholar
3.Graves, GR, Baskett, MB.Nonimmune hydrops fetalis: antenatal diagnosis and management. Am J Obstet Gynecol 1984; 148: 563–565.Google Scholar
4.Szeto, HH.Maternal-fetal pharmacokinetics and fetal dose-response relationships. Ann NY Acad Sci 1989; 562: 42–55.CrossRefGoogle ScholarPubMed
5.Owen, J, Colvin, EV, Davis, RO.Fetal death after successful conversion of fetal supraventricular tachycardia with digoxin and verapamil. Am J Obstet Gynecol 1988; 158: 1169–1170.Google Scholar
6.Allan, LD, Chita, SK, Sharland, GK, Maxwell, D, Priestley, K.Flecainide in the treatment of fetal tachycardias. Br Heart J 1991; 65: 46–48.Google Scholar
7.Weiner, CP, Thompson, MI.Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. Am J Obstet Gynecol 1988; 158: 570–573.CrossRefGoogle ScholarPubMed
8.Gembruch, U, Hansmann, M, Bald, R.Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs. Fetal Ther 1988; 3: 210–215.Google Scholar
9.Dumesic, DA, Silverman, NH, Tobias, S, Golbus, MS.Transplacental cardioversion of fetal supraventricular tachycardia with procainamide. New Engl J Med 1982; 307: 1128–1132.CrossRefGoogle ScholarPubMed
10.van Engelen, AD, Weijtens, O, Brenner, JI, Kleinamn, CS, Copel, JA, Stoutenbeek, P, Meijboom, EJ.Management outcome and follow-up of fetal tachycardia. J Amer Coll Cardiol 1994; 24: 1371–1375.Google Scholar
11.Gembruch, U, Redel, DA, Bald, R, Hansmann, M.Longitudinal study in 18 cases of fetal supraventricular tachycardia: Dop-pler echocardiographic findings and pathophysiologic implications. Am Heart J 1993:125:1290–1301.CrossRefGoogle Scholar